Advances and perspectives in the field of gene transfer technology

Drug News and Perspectives

Volumn 19, Issue 6, 2006, Pages 359-368

  Romano, Gaetano ^a  

^a Laboratory of Molecular Neurovirology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ADENOVIRUS VECTOR; ANGIOPOIETIN; AROMATIC LEVO AMINO ACID DECARBOXYLASE; ASPARTOACYLASE; BONE MORPHOGENETIC PROTEIN 2; BRAIN DERIVED GROWTH FACTOR; CILIARY NEUROTROPHIC FACTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; FOLLISTATIN; GLUCAN 1,4 ALPHA GLUCOSIDASE; GLUTAMATE DECARBOXYLASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LENTIVIRUS VECTOR; MACROPHAGE INFLAMMATORY PROTEIN 2; MATRIX METALLOPROTEINASE INHIBITOR; PIGMENT EPITHELIUM DERIVED FACTOR; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; RETROVIRUS VECTOR; SOMATOMEDIN C; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR RUNX1; VASCULOTROPIN; VIRUS VECTOR; ZINC FINGER PROTEIN;

CANAVAN DISEASE; CANCER THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; CONFERENCE PAPER; DEGENERATIVE DISEASE; DRUG SAFETY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; IMMUNIZATION; MEDICAL RESEARCH; MEDICAL SOCIETY; NONHUMAN; NONVIRAL GENE THERAPY; PARKINSON DISEASE; STEM CELL; TRANSPOSON;

ANIMALS; CARDIOVASCULAR DISEASES; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC DISEASES, INBORN; GENETIC VECTORS; HUMANS; NEOPLASMS; NEURODEGENERATIVE DISEASES; STEM CELL TRANSPLANTATION;

EID: 33748799734     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (127)

1. Sterman, D.H., Recio, A., Haas, A. et al. Results of a clinical trial of adenoviral-interferon-beta gene therapy for malignant mesothelioma and malignant pleural effusions. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 1106.
2. Albeida, S.M., Haas, A., Gillespie, C. et al. High rate of anti-tumor responses in a phase I clinical trial of adenoviral-interferon-beta gene transfer for malignant mesothelioma (MM) and malignant pleural effusions (MPE). Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 1108.
3. Senzer, N., Chang, K., Swisher, S. et al. Bi-modality induction of TNF-alpha: Neoadjuvant chemotherapy and TNFerade[TM] in patients with locally advanced, respectable esopharyngeal carcinoma. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 288.
4. Senzer, N., Lamont, J. and Nemunaitis, J. Adenoviral-mediated p53 gene therapy (Advexin) in a patient with Li-Fraumeni syndrome with a mixed germ cell tumor: Tolerability and response. Proc Am Soc Gene Ther, 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 289.
5. Fujita, T., Teh, B.S., Timme, T.L. et al. Long-term T cell activation following combined in situ gene therapy and intensity-modulated radiotherapy compared to gene therapy as mono-therapy in prostate cancer patients. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 43.
6. Nemunaitis, J., Senzer, N., Shen, J. et al. Clinical study of personalized therapeutics based on genomic/proteomic profiling. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 51.
7. Senzer, N., Nemunaitis, J., Macko, J. et al. TNFerade[TM] in pancreas cancer: Local activation with systemic potential. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 54.
8. Nemunaitis, J., Schiller, J., Ross, H. et al. A phase 2 randomized study of GM-CSF gene-modified autologous tumor cell immunotherapy (CG8123) with and without low-dose cyclophosphamide in advanced stage non-small cell lung cancer. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 630.
9. Gonzalez-Aseguinolaza, G., Ruiz, M., Olague, C. et al. Viral shedding after intratumoral injection of adenoviral vectors to patients with cancer. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 625.
10. Nemunaitis, J., Jahan, T., Ross, H. et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX immunotherapy in advanced stage non-small cell lung cancer. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 631.
11. Freytag, S.O., Kim, J.H., Stricker, H. et al. Phase I study of replication-competent adenovirus-mediated suicide gene therapy in combination with conformal radiotherapy for the treatment of intermediate- to high-risk prostate cancer: Two year efficiency results. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 724.
12. Zhang, S., Xiao, S., Sun, Y. et al. Clinical trial of recombinant adenovirus-p53 (Gendicine) combined with radiotherapy in nasopharyngeal carcinoma patients. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 726.
13. Nemunaitis, J., Pappen, B., Arzaga, R. et al. 10 year follow-up of 146 advanced stage NSCLC patients who received adenoviral based therapy. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 838.
14. Fujita, T., Teh, B.S., Timme, T.L. et al. Combining in situ gene therapy with radiotherapy and hormonal therapy in the treatment of stage DI prostate cancer. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 923.
15. Nemunaitis, J., Bier-Laning, C., Clayman, G.L. et al. Prognostic determinants associated with efficacy of adenoviral p 53 gene therapy in patients with recurrent squamous cell carcinoma of the head and neck. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 943.
16. Nemunaitis, J., Dillman, R.O., Schwarzenberger, P.O. et al. Phase II study of Lucanix[TM] a transforming growth factor beta2 (TGF-beta2) antisense gene modified allogeneic tumor cell vaccine in non-small cell lung cancer (NSCLC). Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 1104.
17. Alvarez, R.D., Barnes, M.N., McCombs, C. et al. A phase I clinical trial of an IL-12 gene plasmid formulated with a novel lipopolymeric gene delivery system for intraperitoneal treatment of recurrent ovarian cancer. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 1105.
18. Onodera, M., Kaneko, S., Otsu, M. et al. Gene therapy clinical trials for relapsed leukemia with infusions of the suicide-gene transduced donor lymphocytes in Japan. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 1107.
19. Lynne, M. Targeting CYPIB1 with a therapeutic cancer vaccine: Results of preclinical and clinical studies. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 1109.
20. McPhee, S.W.J., Janson, C.G., Li, C. et al. The systemic human response to intraparenchymal administration of AAV. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 904.
21. Otsu, M., Nakajima, S., Kida, M. et al. Stem cell gene therapy with no pre-conditioning for the ADA-deficiency patients leads to generalized detoxification and delayed, but steady hematological reconstitution. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 1088.
22. Schwarzwaelder, K., Schmidt, M., Ott, M.G. et al. In vivo expantion of MDS/Evl1, PRDM16 and SETBP1 integration clones in successful chronic granulomatous disease (CGD) gene therapy trial. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 723.
23. Brantly, M.L., Spencer, T., Spencer, C.T. et al. Safety and bioactivity of rAAV-hAAT in alpha-1 antitrypsin-deficient patients in a phase I clinical trial. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 728.
24. Maus, M.V., Mingozzi, F., Sabatino, D.E. et al. T cell responses to AAV vector capsid in normal donors and subjects who have undergone liver-directed AAV-mediated gene transfer. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 730.
25. Chinen, J., Davis, J., deRavin, S.S. et al. Immunologic improvement after gene therapy in 3 patients with X-linked severe combined immunodeficiency. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 806.
26. Rebello, T., Afable, C., Callahan, S. et al. Phase II clinical trial demonstrates the safety and tolerability of multiple doses of autologous CD4+ T cells transduced with VRX496, a lentiviral vector delivering anti-HIV antisense in patients failing 1 or more HAART treatment. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 755.
27. van Lunzen, J., Glaunsinger, T., Hermann, F. et al. Targeting viral entry in gene therapy of HIV-infection. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 756.
28. Kaplitt, M.G., Eidelberg, D., Feigin, A. et al. Improvements in clinical and radiographic outcomes in a phase I study of AAV-GAD gene therapy for Parkinson's disease. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 727.
29. Romano, G., Micheli, P., Pacilio, C. and Giordano, A. Latest developments in gene transfer technology: Achievements, perspectives, and controversies over therapeutic applications. Stem Cells 2000, 18: 19-39.
30. Romano, G., Pacilio, C. and Giordano, A. Gene transfer technology in therapy: Current applications and future goals. Stem Cells 1999, 17: 191-202.
31. Romano, G. Gene transfer in experimental medicine. Drug News Perspect 2003, 16: 267-76.
32. Romano, G. Current development of lentiviral-mediated gene transfer. Drugs News Perspect 2005, 18: 128-34.
33. Check, E. Second cancer case halts gene-therapy trials. Nature 2003, 421: 305.
34. McCormack, M.P. and Rabbitts, T.H. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2004, 350: 913-22.
35. Knorr, D. Serious adverse event on NIH human gene transfer protocol n. 9512-139. A phase I study of adenovector mediated gene transfer to liver in adults with partial ornitine transcarbamylase deficiency. Memorandum of 21 September 1999, Office of Recombinant DNA activities at NIH.
36. Brenner, M. Gene transfer by adenovectors. Blood 1999, 94: 3965-7.
37. Romano, G. The controversial role of adenoviral-mediated gene transfer in gene therapy programs: Where do we stand? Drugs News Perspect 2006, 19: 99-106.
38. DeSilva, A.D., Wiebe, L.I., Shi, C.X. et al. Targeting adenoviral vectors for use in breast cancer therapy. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 654.
39. 1-based attachment protein for improved systemic gene delivery. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 15.
40. Mei, Y.F. Replication competent Ad11 vectors possess a high potential for human cells targeted cancer therapy. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 135.
41. Mitrofanova, E.E., Unfer, R.C., Carvour, M. et al. Increased GFP gene delivery to human prostate cancer cells using transcomplementing adenoviral vectors. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 132.
42. Matsunaga, A., Ueda, Y., Yoneyama, Y. et al. Cancer immunotherapy against murine squamous cell carcinoma with dendritic cells activated by Sendai virus. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 628.
43. Fujihara, A., Kurooka, M., Miki, T. et al. Eradication of renal cell carcinoma in mice mediated by NK cell activation using inactivated Sendai virus particle (HVJ-E). Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 279.
44. Lanuti, M., Goodwin, J.M. and Tanabe, K.K. Combined oncolysis and anti-angiogenesis gene therapy using a herpes simplex virus expressing endostatin in a murine lung cancer model. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 656.
45. Fu, X., Tao, L. and Zhang, X. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 157.
46. Voss, T.T., Bobbin, K.R., Brodie, C. et al. Delivery of oncolytic herpes simplex virus to infiltrate brain tumor sites via neuronal stem cells. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 1072.
47. Ungerechts, G., Springfeld, C., Fielding, A. et al. Next generation measles virus vecotrs for oncolytic therapy: Targeted, armed and stealth. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 968.
48. Liu, C., Sarkaria, J.N. and Allen, C. Combination of oncolytic measles virus strains and radiation therapy has synergisitc activity in the treatment of glioblastoma multiforme. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 44.
49. Dong, X.D.E., O'Malley, M.E., Chalikonda, S. et al. Inhibition of ovarian tumor growth following treatment with an oncolytic vaccinia virus. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 772.
50. Faneca, H., Cabrita, A., Simones, S. et al. Antitumoral activity mediated by a lipid-based gene delivery system containing therapeutic genes. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 636.
51. Yang, Z.H., Sato, T., Koyama, Y. et al. Development of Chitosan nanoparticles for gene delivery system. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 197.
52. Grosse, S., Elbs, M., Wong, J. et al. Receptor-targeting smart vectors for efficient gene transfer to tumors. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 1080.
53. Belur, L.R., Buske, T., Sorensen, B. et al. Sleeping Beauty-mediated gene therapy for colorectal cancer. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 958.
54. Gommas, W.M., McLaughlin, P.M.J., Cool, R. et al. Down-regulating the epithelial glycoprotein-2 promoter utilizing engineered zinc finger protein transcription factors. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 1000.
55. Athanasopoulos, T., Graham, I., Trollet, C. et al. Development of novel adeno-associated viral (rAAV) vectors encoding optimized microdystrophin cDNAs for Duchenne muscular Dystrophy (DMD). Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 907.
56. Kurai, T., Hisayasu, S., Hirai, Y. et al. A single unilateral injection of AAVI-ASA and AAV1-FGE vectors into the hippocampus results in bilateral expression and widespread distribution of ASA and prevention of sulfatide storage in the whole brain of MLD model mice. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 407.
57. Qiao, C., Li, J., Zhu, T. et al. Efficient transfer to peripheral nervous system via systemic delivery of AAV vectors. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 246.
58. Vanden Driessche, T., Thorrez, L., Acosta-Sanchez, A. et al. Widespread and efficient delivery to the heart and liver using AAV serotype 9: implications for cardiovascular disease and hemophilia. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 24.
59. Cardone, M., Polito, V.A., Pepe, S. et al. Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene therapy. Proc Am Soc Gene Ther, 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 209.
60. D'Apolito, D., Acuto, S., Di Marzio, R. et al. Sea urchin sns chromatin insulator prevents silencing and position effect variegation of oncoretroviral vectors transgene expression in murine erythroid cell line. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 321.
61. Sagi, S., Picard-Maureau, M., Dorries, R. et al. A new retroviral gene therapy-approach for cystinuria research. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 221.
62. Robert, E., Lalanne, M., Lamrissi-Garcia, I. et al. Successful gene therapy of a mouse model of congenital erythropoietic porphyria with an erythroid-specific lentiviral vector. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 61.
63. Yant, S.R., Huang, Y., Akache, B. et al. Directed transposon integration in human cells. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 389.
64. Aronovich, E.L., Bell, J.B., Belur, L.R. et al. Sleeping Beauty transposon-mediated long-term alpha-iduronidase expression and correction of lysosomal pathology in the murine model of mucopolysaccharidosis (MPS) type I. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 389.
65. Brondani V. and Segal, D. Assessment of Zinc finger-FOKI chimeric endonuclease activity using a single annealing assay in mammalian cells. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 1015.
66. Davis, B.R., Prokopishyn, N.L., Rosenberg, J. et al. Towrds gene correction for Wiskott-Aldrich syndrome using designed zing finger endonucleases. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 1040.
67. Lawlor, P.A. and During, M.J. Gene therapy for Parkinson's disease. Expert Rev Mol Med 2004, 2004: 1-18.
68. Janson, C., McPhee, S., Bilaniuk, L. et al. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther 2002, 13: 1391-412.
69. Romano, G. Current development of adeno-associated viral vectors. Drugs News Perspect 2005, 18: 311-6.
70. Janelsins, M.C., Mastrangelo, M.A., Park, K.M. et al. Revealing the role(s) of TNF-alpha in early Alzheimer's disease via rAAV-mediated hippocampal gene transfer in a triple transgenic mouse model. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 248.
71. Fowlkes, K.L., Mastrangelo, M.A., Narrow, W.C. et al. Devising Abeta-specific passive immunization strategies for Alzheimer's disease using rAAV vector-mediated scFv antibody delivery. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 247.
72. Kells, A.P., Henry, R.A., Hughes, S.M. et al. Protection against Huntington's disease progression: AAV-mediated delivery of biotherapeutics. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 250.
73. Lu, Y., Adams, R., Sun, W. et al. Targeting of viral vectors to motor neurons by botulinum toxin binding domain to treat ALS. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 901.
74. Acsadi, G., Anguelov, R., Li, X. Et al. Hydrodynamic limb vein delivery of naked IGF-1 plasmid DNA provides therapeutic benefit in SOD1(G93A) murine ALS model. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 420.
75. Naash, M., Ballard, R.M., Skaggs, J. et al. Non-viral gene transfer for hereditary retinal degeneration. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 882.
76. Rakoczy, E.P., Lai, C.M., Shen, W.Y. et al. AAV-mediated sFLT-1 gene therapy for ocular neovascularization: Longevity, toxicity and efficacy results from mice and monkeys. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 418.
77. Allocca, M., Di Vicino, U., Domenici, L. et al. AAV-mediated gene transfer of constitutively and pharmacologically-activated glial cell-derived neurotrophic factor receptor to inhibit retinal degeneration. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 885.
78. Forsayeth, J.R., Eberling, J.L., Sanftner, L.M. et al. A dose-response study of AAV-hAADC therapy in Parkinsonian monkeys. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 241.
79. Ishida, A., Koike, H. and Morishita, R. Gene therapy for Parkinson's disease by in vivo plasnid transfer of human hepatocyte growth factor in primate model. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 416.
80. Su, H., Yeghiazarians, Y., Lee, A. et al. AAV mediated hypoxia-inducible VEGF expression and neovascular formation in ischemic pig myocardium. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 228.
81. Kashiwakura, Y., Cho, H.C., Azene, E. et al. Gene transfer of a synthetic pacemaker into the heart: A novel strategy for biological pacing. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 231.
82. Nguyen, T., Daniels, J., Merritt, L. et al. Short-term, in vivo correction of VLCAD deficiency in mice: Steps toward a gene therapy for cardiomyopathy. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 232.
83. Li, W., Ma, N., Ong, L. et al. Conjugating polymer vector to magnatic nanobeads enhances local gene expression in the heart. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006. Abst 233.
84. Lebeche, D., Sakata, S., Sakata, Y. et al. Gene expression profiles in diabetic cardiomyopathy following SERCA2a gene transfer. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 237.
85. Cherqui, S., Thorpe, C., Kurian, S.M. et al. Lentiviral vector delivery of vMIP-II using both transplanted endothelial and progenitor cells enhances a robust and functional angiogenesis in vivo. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4. Baltimore) 2006, Abst 26.
86. Mori, S., Zhu, X., Gibson, G. et al. Effect of AAV6-mediated TIMP-2 overexpression in a murine model of heart failure. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 29.
87. Cheng, W., Hegge, J.O., Subbotin, V. et al. Towards a gene therapy treatment for peripheral vascular disease: High level of expression of angiogenic genes in rat limb muscle following intravenous delivery of plasmid NAs. Proc Am Soc Gene Ther, Vol. 9 Abst 880.
88. Freguia, C.F., Schuettrumpf, J., Baila, S. et al. Effects of continuous expression of activated protein C (APC) in novel murine thrombosis models. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 879.
89. Sharif, F., Hynes, S., McMahon, J. et al. Prolonged adenovirus and adeno-associated virus-mediated gene delivery to rabbit iliac arteries using gene-eluting stints: A direct comparison. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 874.
90. Hoshino, K., Ly, H.Q., Pomerantseva, I. et al. In vivo fluorescence tracking system for cardiac stem cell therapy. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 230.
91. D'Costa, J., Friedman, A.D., Zambidis, E. et al. RUNX1 increases proliferation of embryoid bodies derived from human embryonic stem cells. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 342.
92. Teng, B., Zsigmond, E. and Jackson, K. Mouse embryonic endothelial progenitor cells home to to atherosclerotic lesions after intravenous delivery. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 1050.
93. Vanderbyl, S.L., Sullenbarger, B., MacDonald, N. et al. The ACE system, a mammalian artificial chromosome engineering technology: Delivery and transgene expression in human adult and embryonic stem cells. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 346.
94. Sunyog, A.M., Wolfe, D., Wechuck, J. et al. A platform for gene delivery to embryonic stem cells using HSV. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 355.
95. Loo, Y., Sampathkumar, S.G., Atukorale, P. et al. Engineering of cell surface sialic acids for polymeric gene delivery. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 356.
96. Ohbayashi, F. and Mitani, K. Chromosomal integration sites of double-stranded linear DNA in mouse ES cells. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 386.
97. Wilber, A., Linehan, J.L., Xingful, X. et al. Effective genetic engineering of human embryonic stem cells using the Sleeping Beauty transposon system. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 95.
98. Paez-Cortex, J.R., Tian, C. and Iacomini, J. Characterization of peripheral regulatory T cell phenotype generated in molecular chimeras by gene therapy. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 1008.
99. Weinreich, M.A., Lintmaer, I., Wang, L. et al. Growth factor receptors as regulators of hematopoiesis. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 1011.
100. Scherr, M., Beutel, G., Battmer, K. et al. Immortalization of murine hematopoietic stem and progenitor cells by AML1-ETO and HoxB4. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 1012.
101. Cohen-Haguenauer, O., Peault, B., Bauche, C. et al. In vivo repopulation ability of genetically corrected bone marrow cells from Fanconi anemia patients. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 1052.
102. Zhao, Y., Zheng, Z., Cohen, C.J. et al. Recognition of tumor antigens by in vivo developed T cells from hematopoietic stem cells retrovirally transduced with TCR genes. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 454.
103. Verbeek, B., Southgate, T.D., Milsom, M.D. et al. Drug selection of hematopoietic cells by regulated MGMT activity. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 669.
104. Shou, Y., Gray, J., Agricola, B. et al. Selection of hematopoietic progenitor and stem cells in transplanted rhesus macaques using MGMT and HoxB4 lentiviral vectors. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 69.
105. Perez, E., Jouvenot, Y., Miller, J.C. et al. Towards gene knock out therapy for AIDS/HIV: Targeted disruption of CCR5 using engineered zinc finger protein nucleuses (ZFNs). Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 758.
106. Robert, E., Richard, E., Ged, C. et al. Murine retroviral but not human cellular promoters induce in vivo erythroid-specific promoter deregulation that can be prevented by insulators. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 790.
107. Anderson, J.S., Vermeulen, A., Karpilow, J. et al. Complete suppression of CCR5 expression and inhibition of HIV-1 infection by transfected and lentiviral vector expressed shRNAs. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 800.
108. Kumar, S., Nagy, T.R. and Ponnazhagan, S. Ex vivo mesenchymal stem cell therapy with AAV2 encoding BMP-2 enhances bone regeneration in ovariectomized mouse model. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 586.
109. Kimelman, N., Oskouian, R.J., Ziberman, Y. et al. Genetically engineered adult stem cells and hybrid scaffolds as a platform for intervertebral disc regeneration. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 455.
110. Oskouian, R.J., Pelled, G., Zilberman, Y. et al. Novel, injectable, gene tically engineered stem cell-based system for anterior spinal fusion. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 450.
111. Zachos, T.A., Weisbrode, S.E. and Bertone, A. Mesenchymal stem cell-mediated gene delivery of bone morphogenic protein-2 in alginate in an articular fracture model. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 1044.
112. Chemaly, E.R., Pomerantseva, I., Yoneyama, R. et al. Tracking and gene expression profile of bone marrow mesenchymal stem cells injected into pig myocardium by magnetic resonance imaging and laser-capture microdissection. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 1042.
113. Nixon, A.J. and Haupt, J.L. Gene-enhanced mesenchymal stem cells for the treatment of tendinitis. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 1048.
114. Ikemoto, M., Fukada, S., Uezemi, A. et al. Transplantation of SM/C-2.6+ satellite cells transduced with micro-dystrophin CS1 cDNA by lentiviral vector into mdx mice. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 39.
115. Rizo, L., Shilling, C., Haidet, A. et al. Recombinant AAV gene delivery of follistatin for muscle enhancement in models of muscular dystrophy. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 914.
116. Emmanuel, R., Safa, B., Gaelle, D. et al. Gene therapy of glycogenosis type 2 using SIN-lentiviral vectors. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 910.
117. Chen, Z.J. and Padidam, M. Lentiviral vector delivery of the RheoSwitch therapeutic system for inducible transgene expression. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 882.
118. Wang, C.H., Yin, G.C., Xiao, X. et al. Neural progenitor cells can be genetically modified by a novel double-stranded adeno-associated viral (AAV) vectors. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 1047.
119. Henry, R.A., Hughes, S.M., Faull, R.L.M. et al. AAV-BDNF augments neurogenesis in both the normal adult rat brain and the quinolinic acid lesion model of Huntington's disease. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 451.
120. Tanaka, S., Kasai, K. and Chiocca, A. Real-time visualization of neuronal differentiation and neurite projection using an indicator HSV amplicon vector. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 158.
121. Tretiakova, A. and Padidam, M. Site-specific integration of immortalization genes in human adult stem cells mediated by Direct. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 357.
122. Hassani, Z., Alfama, G., Francois, J.C. et al. Inhibition of thyroid hormone receptors in the neural stem cells of newborn and adult mice in vivo: Consequences on target gene expression. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 351.
123. Vandenberge, L.H., Breous, K., Gao, PG.P. et al. Novel vectors for gene therapy: Covering the spectrum of primate AAV diversity. Proc Am Soc Gene Ther, 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 744.
124. Lu, Y., Sun, X., Bish, L.T. et al. Molecular mechanism responsible for high level transgene expression in murine and non-human primate liver with the second generation of novel AAV serotype vectors. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 101.
125. Hauck, B., Mingozzi, F., Arruda, V. et al. Investigation of biochemical factors that may influence immunogenicity of AAV2 vectors. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 110.
126. Romano, G., Claudio, P.P., Tonini, T. and Giordano, A. Human immunodeficiency virus type 1 (HIV-1) derived vectors: Safety considerations and controversy over therapeutic applications. Eur J Dermatol 2003, 13: 424-9.
127. Ryu, B.Y., Gray, J.T., Bodine, D.M. and Nienhuis, A.W. Activation of the LMO2 gene in human lymphoid cells by rAAV-mediated targeted insertion of a single LTR expression cassette into the first intron. Proc Am Soc Gene Ther 9th Annu Meet (May 31-June 4, Baltimore) 2006, Abst 102.